Meeting
2013 ASCO Annual Meeting
A phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Authors
Masafumi Ikeda
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Masafumi Ikeda , Akihiro Sato , Nobuo Mochizuki , Kayo Toyosaki , Chika Miyoshi , Rumi Fujioka , Shuichi Mitsunaga , Satoshi Shimizu , Izumi Ohno , Hideaki Takahashi , Hiroyuki Okuyama , Hiromi Hasegawa , Shogo Nomura , Toshiki Ohkubo , Satoshi Yomoda , Satoshi Kishino , Hiroyasu Esumi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
000005787
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2559)
DOI
10.1200/jco.2013.31.15_suppl.2559
Abstract #
2559
Poster Bd #
4C
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.
First Author: Yousuke Nakai
Poster
2018 Gastrointestinal Cancers Symposium
A phase I fixed-dose feasibility study of MK615 and gemcitabine in patients with advanced or metastatic pancreatic cancer.
First Author: Ichiro Moriyama
Poster
2018 Gastrointestinal Cancers Symposium
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
First Author: Suguru Yamada
Poster
2017 Gastrointestinal Cancers Symposium
Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.
First Author: Weijia Fang